Conferences - Results from #980

Viewing 981-1000 of 11745 articles

ASCO GU 2024: Patient-Reported HRQoL in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate + Prednisone and Apalutamide After Radical Prostatectomy

ASCO GU 2024: Long-Term Results of Dose Escalation (80 vs 70 Gy) Combined with Long-Term Androgen Deprivation in High-Risk Prostate Cancer: GETUG-AFU 18 Randomized Trial

ASCO GU 2024: Building a Predictive Model for Outcomes with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer Using VISION Data: Preliminary Results

ASCO GU 2024: The Survival Outcomes for Men with Metastatic Castration-Resistant Prostate Cancer with and Without Homologous Recombination Deficiencies Treated with Radium-223: Princess Margaret Cancer Centre Experience

ASCO GU 2024: Barriers and Facilitators to First-Line Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer: The IMPLEMENT Study

ASCO GU 2024: Rate of Hospitalization and Length of Hospital Stay During and Post Docetaxel for Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer Using ARASENS

ASCO GU 2024: BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC Bearing HRR Mutations

ASCO GU 2024: CONTACT-02: Phase 3 Study of Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy in Patients with mCRPC

ASCO GU 2024: Estimating Median Overall Survival of Apalutamide Compared to Placebo in Metastatic Hormone-Sensitive Prostate Cancer Populations: Statistical Extrapolations of the TITAN Study

ASCO GU 2024: Homologous Recombination Repair Gene Mutation Testing Patterns and Treatment Selection from a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2024: Mature Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

ASCO GU 2024: Interaction of Age and Benefit of Treatment Intensification in Advanced Prostate Cancer: An Aggregate Meta-Analysis of 14 Randomized Trials

ASCO GU 2024: Exploratory Analyses of Homologous Recombination Repair Gene Subgroups and Potential Associations with Secondary Efficacy Endpoints in the HRR-Deficient Population from TALAPRO-2

ASCO GU 2024: Evaluating Early Changes in Circulating Tumor DNA Tumor Fraction as a Value Add to PSA in Predicting Early Progression in mCRPC

ASCO GU 2024: Efficacy of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Single Homologous Recombination Repair Gene Mutations in the PROpel Trial

ASCO GU 2024: CYPIDES Phase 2 Results MK-5684 (ODM-208), a CYP11A1 Inhibitor, in Patients with mCRPC with and without AR-LBD Mutations

ASCO GU 2024: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel: A Sensitivity Analysis from ARASENS Accounting for Subsequent Therapy

ASCO GU 2024: Radiographic Progression Without PSA Progression in Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis from the ENZAMET Trial (ANZUP 1304)

ASCO GU 2024: Enzalutamide Combination Treatment Suspension in Men with High-Risk Biochemically Recurrent Prostate Cancer: Outcomes from EMBARK

ASCO GU 2024: Underutilization of ADT Intensification for the Treatment of Men with mHSPC: A Systematic Review of Real-World Database Studies

45
46
47
48
49
50
51
52
53
54